• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗生素治疗、肠道需氧微生物群与Balb/c小鼠实验性肉瘤L-1生长

Antibiotic treatment, intestinal aerobic microflora and experimental sarcoma L-1 growth in Balb/c-mice.

作者信息

Roszkowski K, Ko H L, van der Waaij D, Roszkowski W, Jeljaszewicz J, Pulverer G

机构信息

Institute of Lung Diseases, Warsaw, Poland.

出版信息

Zentralbl Bakteriol Mikrobiol Hyg A. 1987 Jul;265(3-4):378-84. doi: 10.1016/s0176-6724(87)80256-0.

DOI:10.1016/s0176-6724(87)80256-0
PMID:3314263
Abstract

The present paper deals with the influence of a 10 days treatment with mezlocillin, piperacillin, cefotaxime, clindamycin or gentamicin on the endogenous intestinal microflora of Balb/c-mice and on the local growth of sarcoma L-1 tumor. Clindamycin and gentamicin demonstrated no influence, whereas cefotaxime and piperacillin caused the eradication of gram-negative resp. gram-positive bacteria but these antibiotics didn't produce a growth inhibition of local L-1 sarcoma tumor. The oral or parenteral application of mezlocillin (a 3 days treatment was sufficient) eradicated the complete aerobic and anaerobic intestinal microflora. This effect was significantly correlated with an increase of the cecum weight and the inhibition of local tumor growth. Possible mechanisms of these effects are discussed.

摘要

本文探讨了美洛西林、哌拉西林、头孢噻肟、克林霉素或庆大霉素进行10天治疗对Balb/c小鼠肠道内源性微生物群以及肉瘤L-1肿瘤局部生长的影响。克林霉素和庆大霉素未显示出影响,而头孢噻肟和哌拉西林导致革兰氏阴性菌和革兰氏阳性菌的根除,但这些抗生素并未对局部L-1肉瘤肿瘤产生生长抑制作用。口服或肠胃外应用美洛西林(3天治疗就足够)可根除整个需氧和厌氧肠道微生物群。这种效应与盲肠重量增加和局部肿瘤生长抑制显著相关。文中讨论了这些效应可能的机制。

相似文献

1
Antibiotic treatment, intestinal aerobic microflora and experimental sarcoma L-1 growth in Balb/c-mice.抗生素治疗、肠道需氧微生物群与Balb/c小鼠实验性肉瘤L-1生长
Zentralbl Bakteriol Mikrobiol Hyg A. 1987 Jul;265(3-4):378-84. doi: 10.1016/s0176-6724(87)80256-0.
2
Antibiotics and immunomodulation: effects of cefotaxime, amikacin, mezlocillin, piperacillin and clindamycin.抗生素与免疫调节:头孢噻肟、阿米卡星、美洛西林、哌拉西林及克林霉素的作用
Med Microbiol Immunol. 1985;173(5):279-89. doi: 10.1007/BF02124944.
3
Effects of cefotaxime, clindamycin, mezlocillin, and piperacillin on mouse sarcoma L-1 tumor.头孢噻肟、克林霉素、美洛西林和哌拉西林对小鼠肉瘤L-1肿瘤的影响。
Cancer Immunol Immunother. 1984;18(3):164-8. doi: 10.1007/BF00205506.
4
Intestinal microflora of BALB/c-mice and function of local immune cells.
Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Nov;270(1-2):270-9. doi: 10.1016/s0176-6724(88)80163-9.
5
Influence of 12 antibiotics on antitumor immunity in BALB/c-mice.12种抗生素对BALB/c小鼠抗肿瘤免疫的影响。
Zentralbl Bakteriol. 1992 Jan;276(2):280-7. doi: 10.1016/s0934-8840(11)80015-0.
6
Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci.
J Chemother. 1991 Oct;3(5):289-94. doi: 10.1080/1120009x.1991.11739108.
7
[The effect of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime].
Arzneimittelforschung. 1991 Aug;41(8):831-8.
8
In vitro comparison of mezlocillin and piperacillin plus tobramycin or gentamicin versus 100 gram-negative nosocomial bloodstream isolates.
Am J Infect Control. 1990 Aug;18(4):250-6. doi: 10.1016/0196-6553(90)90166-p.
9
Increased minimum inhibitory concentrations with anaerobiasis for tobramycin, gentamicin, and amikacin, compared to latamoxef, piperacillin, chloramphenicol, and clindamycin.与拉氧头孢、哌拉西林、氯霉素和克林霉素相比,厌氧环境下妥布霉素、庆大霉素和阿米卡星的最低抑菌浓度升高。
Chemotherapy. 1985;31(3):204-10. doi: 10.1159/000238337.
10
[Comparative study of the in vitro activity of dibekacin, piperacillin, cefotaxime and cefuroxime on gram-negative bacteria].
G Batteriol Virol Immunol. 1983 Jul-Dec;76(7-12):239-45.